RxDoctor Payments Data

Evans Azagidi

Family · Las Vegas, NVNPI 1528530763

Payments from drug & device makers

$1,918in general payments, 2019–2025

Across 101 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$362
  • Otsuka America Pharmaceutical, Inc.$330
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291
  • Neurocrine Biosciences, Inc.$162
  • AbbVie$158
  • Vanda Pharmaceuticals Inc.$145
  • plus $469 from 12 others

What the payments were for

  • Food & beverage$1,90599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,918 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$18,665
Medicare patients
51
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$48,418
VraylarCariprazine Hcl12$17,944
BelsomraSuvorexant12$5,532
Oxcarbazepine42$2,143
Risperidone67$1,555
Quetiapine Fumarate80$995
Aripiprazole46$971
Guanfacine Hcl ErGuanfacine Hcl24$660
Mirtazapine28$495
Divalproex Sodium15$479
Methylphenidate ErMethylphenidate Hcl12$425
Trazodone Hcl21$413
Lorazepam13$315
Citalopram HbrCitalopram Hydrobromide26$308
Bupropion XlBupropion Hcl21$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$362$48,41812 claims
AbbVieVraylar$158$17,94412 claims
Almatica Pharma LLCSertraline Hcl$15$14234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →